Monte Rosa Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
GLUE$10.50-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of operations and comprehensive loss
| Year ended December 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2025 | 2024 |
| Collaboration revenue | $123,672 | $75,622 |
| Operating expenses: | ||
| Research and development | 141,500 | 121,563 |
| General and administrative | 36,380 | 35,171 |
| Total operating expenses | 177,880 | 156,734 |
| Loss from operations | (54,208) | (81,112) |
| Other income: | ||
| Interest income | 12,942 | 10,566 |
| Foreign currency exchange gain, net | 1,484 | 416 |
| Gain on disposal of fixed assets | 59 | — |
| Total other income | 14,485 | 10,982 |
| Net loss before income taxes | (39,723) | (70,130) |
| Income tax benefit (provision) | 1,097 | (2,570) |
| Net loss | $(38,626) | $(72,700) |
| Net loss per share—basic and diluted | $(0.46) | $(0.98) |
| Weighted-average number of shares outstanding used in computing net loss per common share—basic and diluted | 83,071,185 | 73,910,026 |
| Comprehensive loss: | ||
| Net loss | $(38,626) | $(72,700) |
| Other comprehensive loss: | ||
| Provision for pension benefit obligation | (518) | (802) |
| Unrealized gain on available-for-sale securities | 47 | 170 |
| Comprehensive loss | $(39,097) | $(73,332) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.